None listed
Conditions
Interventions
Bloodpressure Standard : ACE-inhibitor or AII-antagonist (irbesartan)
Target: 1 g/dag.
Proteïnuria Intensify antihypertensive therapy
Target: < 0.5 g/dag.
Dyslipidemia Standard: atorvastatine 10 mg
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Patients are eligible for inclusion when they fulfill the following criteria: 1. The subject is at least 18 years old; 2. The subject is diagnosed with CKD with a creatinine clearance estimated by the Cockcroft-Gault equation between 20 and 70 ml/min; 3. The subject is able and willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: Also none of the exclusion criteria can be present. The following conditions are considered exclusion criteria: 1. A renal transplant less than a year before inclusion; 2. Acute renal failure or rapidly progressive glomerulonephritis established by the treating physician; 3. Any malignancy less than five years before inclusion other than basocellular or squamous cell carcinoma of the skin; 4. Participation in other clinical trials requiring the use of study medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Assessment of cardiovascular morbidity (comprised of myocardial infarction, stroke and all vascular interventions, including amputation of an extremity due to vascular insufficiency); 2. Cardiovascular mortality; 3. All cause mortality. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Decline in renal function, this will be established by annual measurement of creatinine clearance by 24-hour urine measurements; 2. Quality of life, will be assessed using a validated questionnaire; 3. Markers of vascular damage: aortic pulse wave velocity, carotid intimal media thickness and the ankle-brachial index. | — |
Contacts
Public ContactArjan Zuilen, van
University Medical Center Utrecht (UMCU), Department of Nephrology, room F03-226 P.O. Box 85500
Outcome results
None listed